Vera Therapeutics shares target raised by Wedbush, cites ‘ORIGIN 3’ enrollment By Investing.com
[ad_1] © Reuters. On Thursday, Wedbush maintained its Outperform rating on Vera Therapeutics (NASDAQ:VERA) and increased the shares price target to $34 from $21. The...
Wedbush anticipates Nasdaq could rally to 20k in 2024 By Investing.com
[ad_1] © Reuters Wedbush’s Ives says Nasdaq could rally to 20k in 2024 As 2024 unfolds, Wedbush anticipates a transformative “Year of AI” poised to...